Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spinal fluid study seeks clues to brain damage after cardiac arrest

NCT ID NCT07481396

Knowledge-focused Sponsor: Chungnam National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to uncover the molecular causes of secondary brain injury in patients who survive cardiac arrest. Researchers will analyze cerebrospinal fluid from 60 participants using advanced techniques to identify changes in genes, proteins, and other molecules. The goal is to find new targets for future treatments, though this is an early-stage observational study, not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could identify new drug targets for preventing brain damage after cardiac arrest.
What could go wrong
This is an early observational study with only 60 participants, so findings may not lead directly to treatments and need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population for this research consists of a highly specific and clinically critical group of patients: Adults who have experienced out-of-hospital or in-hospital cardiac arrest and successfully regained spontaneous circulation (ROSC), but remain at high risk for secondary brain injury.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients receiving post-resuscitation care after out-of-hospital cardiac arrest for secondary brain injury treatment. * Patients without contraindications for lumbar puncture catheter insertion for cerebrospinal fluid (CSF) collection. This includes the absence of: * Uncontrolled diabetes.Coagulation disorders. * Thrombocytopenia (platelet count $\< 100,000). * A history of cirrhosis diagnosis. * Current receipt of low molecular weight heparin. * Current use of platelet inhibitors. * A history of posterior spinal fusion that may interfere with catheter insertion. * Local skin infection or rash at the puncture site. * Signs of systemic infection or sepsis. * A history of lumbar puncture within the past 6 hours. Exclusion Criteria: * Cerebral Edema: Patients with evidence of cerebral edema on a brain computed tomography (CT) scan performed immediately after spontaneous circulation recovery. * Patients who underwent extracorporeal membrane oxygenation (ECMO). * Patients who could not maintain integrated therapy for more than 24 hours after cardiac arrest. * Patients with a history of acute or chronic brain disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac arrest (CA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain hypoxia - ischemia cardiac arrest perinatal asphyxia post-cardiac arrest syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac arrest (CA) Cerebrospinal fluid Hypoxic-ischemic brain injury Multiomics

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chungnam National University Hospital

    RECRUITING

    Daejeon, Jung-gu, 35015, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.